Article Text

Download PDFPDF

Evaluation of an innovative mobile health programme for the self-management of chronic obstructive pulmonary disease (MH-COPD): protocol of a randomised controlled trial
  1. Hang Ding1,
  2. Mohan Karunanithi1,
  3. Derek Ireland1,
  4. Lisa McCarthy2,
  5. Rekha Hakim2,
  6. Kirsten Phillips3,
  7. Rahul Pradhan2,4,
  8. E-Hong Seah2,4,
  9. Rayleen V Bowman2,4,
  10. Kwun Fong2,4,
  11. Philip Masel2,4,
  12. Ian A Yang2,4
  1. 1 The Australian eHealth Research Centre, CSIRO, Brisbane, Queensland, Australia
  2. 2 Metro North Hospital and Health Service, The Prince Charles Hospital, Brisbane, Queensland, Australia
  3. 3 Consumer Health Programs and Partnership, Lung Foundation Australia, Brisbane, Queensland, Australia
  4. 4 University of Queensland Thoracic Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
  1. Correspondence to Dr Hang Ding; hang.ding{at}


Introduction Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally. In outpatient care, the self-management of COPD is essential, but patient adherence to this remains suboptimal. The objective of this study is to examine whether an innovative mobile health (mHealth)-enabled care programme (MH-COPD) will improve the patient self-management and relevant health outcomes.

Methods and analysis A prospective open randomised controlled trial has been designed. In the trial, patients with COPD will be recruited from The Prince Charles Hospital, Brisbane, Australia. They will then be randomised to participate in either the MH-COPD intervention group (n=50 patients), or usual care control group (UC-COPD) (n=50 patients) for 6 months. The MH-COPD programme has been designed to integrate an mHealth system within a clinical COPD care service. In the programme, participants will use a mHealth application at home to review educational videos, monitor COPD symptoms, use an electronic action plan, modify the risk factors of cigarette smoking and regular physical activity, and learn to use inhalers optimally. All participants will be assessed at baseline, 3 months and 6 months. The primary outcomes will be COPD symptoms and quality of life. The secondary outcomes will be patient adherence, physical activity, smoking cessation, use of COPD medicines, frequency of COPD exacerbations and hospital readmissions, and user experience of the mobile app.

Ethics and dissemination The clinical trial has been approved by The Prince Charles Hospital Human Research Ethics Committee (HREC/16/QPCH/252). The recruitment and follow-up of the trial will be from January 2019 to December 2020. The study outcomes will be disseminated according to the Consolidated Standards of Reporting Trials statement through a journal publication, approximately 6 months after finishing data collection.

Trial registration number ACTRN12618001091291.

  • chronic pulmonary obstructive disease
  • randomized controlled trial
  • self-management
  • mobile health

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors The MH-COPD program was designed by IAY, HD, DI, LM, RH, KP and PM. This study protocol was developed by IAY and HD. The first draft of the manuscript was written by IAY and HD. All authors contributed to the design of the clinical study and critical revision of the manuscript.

  • Funding This project is funded by The Prince Charles Hospital Foundation, Brisbane, Australia (Experienced Researcher grant no. ER2015-21).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.